Analysts expect SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) to report $-0.18 EPS on August, 21.They anticipate $1.08 EPS change or 85.71 ...
News
- SELLAS Life Sciences Group, Inc. (SLS) Analysts See $-0.18 EPS
- Celcuity Inc. (CELC) EPS Estimated At $-0.20
... “Celcuity Announces Clinical Trial Collaboration with Puma Biotechnology and West Cancer Center – Business Wire” on October 16, 2018. ... at the 2018 San Antonio Breast Cancer Symposium Evaluating HER2-Negative Breast ...
- EPS for Syros Pharmaceuticals, Inc. (SYRS) Expected At $-0.41
... by: Bizjournals.com which released: “Battle of the biotech bosses: Syros execs face off in 'Lab Olympics' – Boston ... Preclinical Data on SY-1365 at San Antonio Breast Cancer Symposium – Business Wire” on December 07, 2018.
- San Antonio Chamber names interim chairman after CPS CEO's resignation
San Antonio Chamber names interim chairman after CPS CEO's ... security, biotechnology, chemistry, environmental science and engineering.
- BiOasis: Fiscal 1Q Earnings Snapshot
The biotech drug developer posted revenue of $143,500 in the period. Its adjusted revenue was $144,000. In the final minutes of trading on Friday, the ...